Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Grants

Publications

Strosberg, Jonathan, Pamela L. Kunz, Andrew Hendifar, James Yao, David Bushnell, Matthew H. Kulke, Richard P. Baum, et al. “Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.” Eur J Nucl Med Mol Imaging 47, no. 10 (September 2020): 2372–82. https://doi.org/10.1007/s00259-020-04709-x.

PMID
32123969
Full Text

Kim, Richard D., Nilofer S. Azad, Michael A. Morse, Elizabeth Poplin, Amit Mahipal, Benjamin Tan, Sharon A. Mavroukakis, et al. “Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.” Clin Cancer Res 26, no. 14 (July 15, 2020): 3557–64. https://doi.org/10.1158/1078-0432.CCR-20-0426.

PMID
32303539
Full Text

Wang, Shuo, Xiaoli Wang, Xinna Zhou, Herbert Kim Lyerly, Michael A. Morse, and Jun Ren. “DC-CIK as a widely applicable cancer immunotherapy.” Expert Opin Biol Ther 20, no. 6 (June 2020): 601–7. https://doi.org/10.1080/14712598.2020.1728250.

PMID
32033522
Full Text

Kaneko, Kensuke, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, et al. “Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors.” Commun Biol 3, no. 1 (May 8, 2020): 226. https://doi.org/10.1038/s42003-020-0956-7.

PMID
32385408
Full Text

Thorpe, Matthew P., Ari Kane, Jason Zhu, Michael A. Morse, Terence Wong, and Salvador Borges-Neto. “Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.” In J Clin Endocrinol Metab, Vol. 105, 2020. https://doi.org/10.1210/clinem/dgz074.

PMID
31614368
Full Text

Zhou, Xinna, Guoliang Qiao, Jun Ren, Xiaoli Wang, Shuo Wang, Siyu Zhu, Yanhua Yuan, Michael A. Morse, Amy Hobeika, and Herbert Kim Lyerly. “Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients.” Pain 161, no. 1 (January 2020): 127–34. https://doi.org/10.1097/j.pain.0000000000001702.

PMID
31568023
Full Text

He, Zixuan, Shuo Wang, Guoliang Qiao, Xiaoli Wang, Xinna Zhou, Siyu Zhu, Yanhua Yuan, et al. “Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites.” Am J Transl Res 12, no. 7 (2020): 3940–52.

PMID
32774747
Scholars@Duke

Morse, Michael A., Eric Liu, Vijay N. Joish, Lynn Huynh, Mu Cheng, Mei Sheng Duh, Kiernan Seth, Pablo Lapuerta, and David C. Metz. “Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.” Cancer Manag Res 12 (2020): 6607–14. https://doi.org/10.2147/CMAR.S261257.

PMID
32801896
Full Text

Huang, Lefu, Guoliang Qiao, Michael A. Morse, Xiaoli Wang, Xinna Zhou, Jiangping Wu, Amy Hobeika, Jun Ren, and Herbert K. Lyerly. “Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer.” Oncol Lett 18, no. 6 (December 2019): 5717–24. https://doi.org/10.3892/ol.2019.10964.

PMID
31788044
Full Text

Pages